🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are escalating worldwide, with figures suggesting in excess of 82 million infections per year. Particularly high rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This approval signifies a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Results and Global Access

Based on results published in a prominent scientific publication, zoliflodacin eradicated the vast majority of uncomplicated infections. This establishes an equal footing with the current standard treatment, which uses a dual-drug approach. The study enrolled nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to make available and distribute the drug in many developing nations.

Clinicians on the front lines have expressed hope. Having a one-pill regimen of this kind is seen as a "game-changer" for managing the epidemic. This is considered vital to lessen the impact of the infection for individuals and to halt the transmission of untreatable gonorrhoea around the world.